|
KMID : 0191120140290010090
|
|
Journal of Korean Medical Science
2014 Volume.29 No. 1 p.90 ~ p.97
|
|
|
Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study
|
|
Lee Mi-Young
Choi Dong-Seop
Lee Moon-Kyu
Lee Hyoung-Woo
Park Tae-Sun
Kim Doo-Man
Chung Choon-Hee
Kim Duk-Kyu
Kim In-Joo
Jang Hak-Chul
Park Yong-Soo
Kwon Hyuk-Sang
Lee Seung-Hun
Shin Hee-Kang
|
|
|
Abstract
|
|
|
|
We studied the efficacy and safety of acarbose in comparison with voglibose in type 2 diabetes patients whose blood glucose levels were inadequately controlled with basal insulin alone or in combination with metformin (or a sulfonylurea). This study was a 24-week prospective, open-label, randomized, active-controlled multi-center study. Participants were randomized to receive either acarbose (n=59, 300 mg/day) or voglibose (n=62, 0.9 mg/day). The mean HbA1c at week 24 was significantly decreased approximately 0.7% from baseline in both acarbose (from 8.43% ± 0.71% to 7.71% ± 0.93%) and voglibose groups (from 8.38% ± 0.73% to 7.68% ± 0.94%). The mean fasting plasma glucose level and self-monitoring of blood glucose data from 1 hr before and after each meal were significantly decreased at week 24 in comparison to baseline in both groups. The levels 1 hr after dinner at week 24 were significantly decreased in the acarbose group (from 233.54 ± 69.38 to 176.80 ± 46.63 mg/dL) compared with the voglibose group (from 224.18 ± 70.07 to 193.01 ± 55.39 mg/dL). In conclusion, both acarbose and voglibose are efficacious and safe in patients with type 2 diabetes who are inadequately controlled with basal insulin. (ClinicalTrials.gov number, NCT00970528)
|
|
|
KEYWORD
|
|
|
Diabetes Mellitus, Type 2, Acarbose, Voglibose
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|